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1. Introduction
===============

Angiotensin-converting enzyme (ACE, dipeptidyl-peptidase A, kininase II, E.C. 3.4.15.1, DCP1) is a dipeptidyl-carboxypeptidase that belongs to the M2-metalloprotease family. In mammals, this zinc-dependent metalloprotease participates in blood pressure elevation (review in ([@bib7])), generating the vasopressor angiotensin II (Ang II) from the inactive angiotensin I (Ang I), and by inactivating the vasodilator bradykinin. In vertebrates, somatic (sACE) and testicular (germinal) ACE (tACE) have been characterized. These two separate isoforms are transcribed from two alternate promoters within a single gene ([@bib21]), which arose from duplication of an ancestral gene ([@bib22]). Consequently, sACE possesses two domains (termed N-domain and C-domain, respectively) bearing the highly conserved gluzincin motif HExxH, whereas tACE possesses only one, corresponding to the C-terminal domain of sACE. Crystal structures of both the human N-domain ([@bib6]) and tACE ([@bib32]) have shown them to be homologous helical ellipsoids harbouring two large cavities connected by a narrow catalytic channel containing the catalytic zinc and the HexxH motif. Somatic ACE N- and C-domain active sites have distinct enzymatic specificities with respect to *in vivo* and/or synthetic substrates. Indeed, the C-domain is highly selective for Hippuryl-Histidyl-Leucine (HHL) ([@bib42]) whereas the N-domain efficiently cleaves the hemoregulatory peptide Ac-Ser-Asp-Lys-Pro (AcSDKP) ([@bib35]) and Ang 1-7 ([@bib10]). In addition, ACE inhibitors ([@bib13]) and chloride ion dependence ([@bib24]) can discriminate between the two domains. Both sACE and tACE possess a C-terminal transmembrane domain and are membrane-anchored isoforms, though a post-translational shedding releases active solubilized ACE into the extracellular milieu ([@bib17], [@bib33]). A single domain ACE homologue, ACE2, has also been characterized in the human ([@bib14], [@bib39]) and its structure determined ([@bib40]). ACE2 is an essential regulator of heart function ([@bib8]) and has also been identified as a functional receptor for the SARS coronavirus ([@bib29]).

In invertebrates, however, functional ACE-related enzymes exist in insects and in annelids (which belong to the Ecdysozoa and Lophotrochozoa groups, respectively). Interestingly, and though *in silico* evidence suggest the presence of a two-domain ACE-related protein in mosquitoes ([@bib3]), all the cloned genes encode soluble, single active site enzymes ([@bib37], [@bib38], [@bib44]). In the fruit fly *Drosophila melanogaster*, two homologues have been cloned and named *AnCE* ([@bib5]) and *ACER* ([@bib37]) (or *Race*), of which AnCE has had its structure determined ([@bib25]). AnCE and ACER show about 40% amino-acid sequence identities with vertebrate ACEs, share similar enzymatic properties ([@bib4]), acting on a broad range of substrates and play a key role in development ([@bib8]) and reproduction ([@bib15], [@bib23]). Molecular and biochemical data from the leech ACE homologue have related it to the N-domain of mammalian ACE ([@bib34]). However, no functional ACE is present in the genome of the nematode *Caenorhabditis elegans* (*C. elegans*), despite ACN-1, a homologue that lacks ACE-like proteolytic activity, is crucial in development ([@bib2]). Recently, a dicarboxypeptidase, LdDCP, was cloned in a pathogenic unicellular eukaryote, *Leishmania donovani* ([@bib18]). LdDCP, like ACE, is able to cleave a carboxyterminal dipeptide from HHL and is inhibited by captopril, suggesting that ACE may have already been present before the appearance of multicellular organisms. However, LdDCP was not reported to hydrolyse AngI and does not display sequence homology with ACE enzymes. These observations raise questions about the presence of a true ACE in more distant species.

Very surprisingly, *in silico* databank analysis revealed that DNA sequences in bacterial genomes have been annotated as encoding potentially functional ACE-like enzymes. All these sequences display a great similarity despite phylogenetic distance (for references see <http://tolweb.org> and ([@bib12])). The striking sequence conservation in the active region of these putative ACE-like peptidases suggests that the protease activity would be conserved in these ancestral, prokaryotic species. Among them, *Xanthomonas axonopodis* pv. *citri* (*X. citri*) is a phytopathogen gamma-proteobacteria in whose genome an ACE-like encoding sequence has been annotated. In order to gain more insight into stages in ACE evolution and to investigate its putative activity in unicellular organisms, we report the cloning and biochemical characterization of the expressed recombinant enzyme. We have also generated a homology-based model of *Xc*ACE using the structure of tACE to understand the interactions of residues in the active site. This ACE-like enzyme in *X. citri* is, to our knowledge, the first bacterial ACE-like enzyme ever characterized.

2. Materials and methods
========================

2.1. *In silico* analysis
-------------------------

The protein sequence of the leech ACE (*Tt*ACE, Genbank accession no. **[45272589]{.ul}**), the most distant known ACE characterized at the time of the present study, was submitted to similarity searches using the BLAST program suite (tblastn; default parameters) (<http://www.nih.nlm.ncbi.gov/blast>) against all bacterial genomic sequences available at the NCBI server at the time of the study. Alignments were performed using the ClustalW (default parameters) software (<http://www.ebi.ac.uk/clustalw/>). The distance matrix generated into the tree file of ClustalW was used in the drawtree program of the PHYLIP suite and an unrooted tree diagram was generated (<http://bioweb.pasteur.fr/seqanal/interfaces/drawtree-simple>).

2.2. Bacterial strain
---------------------

*X. citri* strain N1 was from the culture collection of the Laboratory of Plant Pathology, Faculty of Agriculture, Shizuoka University, Shizuoka, Japan ([@bib36]).

2.3. DNA extraction
-------------------

Bacterial DNA was obtained as previously described ([@bib9]).

2.4. RNA extraction {#sec1}
-------------------

Total RNA was extracted using the SV total RNA isolation system (Promega).

2.5. Protein extraction
-----------------------

*X. citri* was cultured in YP medium under agitation at 30 °C until an optical density of 0.3 at 620 nm and centrifuged (5000 ×*g*, 30 min). Cells were washed in water, centrifuged, and the pellet resuspended in water in one hundredth of the culture volume. The resulting suspension was passed twice through a French pressure cell at 15,000 lb/in.^2^ (10^8^ Pa) and unbroken cells and debris were removed by 5 min centrifugation at 5000 ×*g*.

2.6. RT-PCR
-----------

To assess the presence of a messenger RNA correponding to the *XcACE* gene, total RNAs (30--40 ng) were treated with RNAse-free DNAse I and reverse transcribed with Superscript III Reverse Transcriptase (Invitrogen). The same amount of nucleic acids (170 ng) was further used in PCR reactions containing 2% DMSO using XcInt-S1 (5′-GCTGCAGCAGATCCCACAGA-3′) and XcInt-AS1 (5′-CTATTGCGTGGGCGTAGGC-3′) as primers. Water was used instead of cDNA as a negative control. PCR products were resolved on an agarose gel stained with ethidium bromide.

2.7. Cloning of *Xc*ACE, construction of the p*Xc*ACE vector and expression in mammalian cell cultures
------------------------------------------------------------------------------------------------------

### 2.7.1. Cloning {#sec2}

Full-length *XcACE* cDNA sequence ([NP 641553](NP641553); GenBank accession no. gi: **[21241971]{.ul}**) was obtained by PCR on *X. citri* DNA (see [Section 2.4](#sec1){ref-type="sec"}). Sense and antisense primers (*XcACE*FL-S1 5′-CTGACCTATTCGGATGCGCTCAAGGAT-3′ and *XcACE*FL-AS2 5′-CTCTAGCCTTCGGCGGACTTCACTGCAAAGGAC-3′) were used (2 pmol each) in a PCR reaction containing 400 ng DNA, 2% DMSO, 20 μM dNTPs, 5 U *Pfu* DNA polymerase (Promega) in 50 μL total volume. Reaction cycling parameters were 94 °C, 3 min; 94 °C, 40 s, 61 °C, 1 min, 72 °C, 4 min for 35 cycles. The expected 2.2 kb product was blunt-end subcloned into the EcoRV site of pcDNA3.1 (Invitrogen) and sequenced with *XcACE* and pcDNA3 specific primers.

### 2.7.2. Construct

Heterologous expression of *Xc*ACE was carried out using mammalian CHO-K1 cells (Invitrogen). Because the start codon is GTG for *XcACE*, it was necessary to change it into the standard ATG, a sequence recognized as an initiation codon by CHO-K1 cells. This substitution mutation (T11A) was realised by PCR using the *Xc*FLAS2.2 (5′-GCT CTA GCC TTC GGC GGA CTT CAA TGC AAG-3′) antisense oligonucleotide and resulted in an in-frame ATG initiation codon. The PCR product was subcloned in pcDNA3.1 and the obtained p*XcACE* plasmid sequenced as described above (see [Section 2.7.1](#sec2){ref-type="sec"}).

### 2.7.3. Expression

CHO-K1 cells were stably transfected with p*XcACE* using lipofectamine 2000 reagent (Invitrogen), and were selected for resistance to Geneticin. Individual resistant colonies producing large amounts of *Xc*ACE were cloned by limiting dilution techniques as described ([@bib43]).

2.8. Biochemical characterization of *Xc*ACE
--------------------------------------------

### 2.8.1. Semi-purification {#sec3}

Both native and recombinant *Xc*ACE were partially purified by ion exchange chromatography. Briefly, native *Xc*ACE was obtained from bacterial protein extract, and secreted recombinant *Xc*ACE from concentrated culture medium of transfected CHO cells (fraction A). The fraction A samples were first desalted on a HiPrep Fast Desalting Column (Amersham Pharmacia Biotech), then fractionated onto a FPLC MonoQ anion-exchange column system (Pharmacia). The resulting fractions showing specific ACE activity were pooled and concentrated. The resulting fractions were named native *Xc*ACE (n*Xc*ACE) and recombinant *Xc*ACE (r*Xc*ACE), respectively. For n*Xc*ACE purification steps, each pooled fractions containing specific ACE activity were analysed by SDS-PAGE.

### 2.8.2. Western blot

Both n*Xc*ACE and r*Xc*ACE (see [Section 2.8.1](#sec3){ref-type="sec"}) were submitted to western blot experiment using a polyclonal antibody (HKCE) raised against the human full-length sACE.

### 2.8.3. Enzymatic assays

ACE activity was assayed using various substrates: HHL (5 mM), as a human ACE C-domain specific substrate, AcSDAcKP (Acetyl-Serine-Aspartyl-Acetyl-Lysine-Proline) (2.5 mM), as an N-domain specific substrate, Ang I (100 μM), as both an N- and a C-domain ACE substrate. Assays were performed at 37 °C for 30 or 60 min. Hydrolysis of \[Leu5\]-enkephalinamide (\[Leu5\]-enk-NH2) (0.8 mM, incubated for 330 min), as an amidated substrate and \[Leu5\]-enkephalin (\[Leu5\]-enk) (0.8 mM, incubated for 30 min), were compared to determine whether *Xc*ACE also exhibits endopeptidase activity. The rate of hydrolysis of all substrates used was determined and quantified using reverse phase HPLC (Waters Co, Milford, MA, USA) as previously described ([@bib1], [@bib20], [@bib43]). The specificity of the reaction was assessed in the presence of 10 μM captopril. The effect of chloride ions (NaCl concentrations from 0 to 1.0 M) on HHL hydrolysis was determined under standard conditions.

### 2.8.4. Inhibition of *Xc*ACE activity by various ACE inhibitors

The inhibition potentials of various tight binding ACE inhibitors (captopril, delaprilat, fosinoprilat, lisinopril, perindoprilat, RXP 407 and enalaprilat) were assessed by determining the IC~50~ values for the fluorogenic substrate Mca-Ala-Ser-Asp-Lys-DpaOH hydrolysis in standard conditions as described previously ([@bib13]). Compounds were pre-incubated with n*Xc*ACE (see [Section 2.8.1](#sec3){ref-type="sec"}) for 1 h and reactions initiated by the addition of 12 μM substrate.

2.9. Modelling of *Xc*ACE
-------------------------

A model of *Xc*ACE was generated by the ESyPred3D server (<http://www.fundp.ac.be/sciences/biologie/urbm/bioinfo/esypred/>) ([@bib26]) using testis ACE (ProteinDataBank pdb code **[1O8A]{.ul}**) as a model. This model was compared with the testis ACE structures ([@bib32], [@bib31]) and the N-domain structure ([@bib6]) and AnCE ([@bib20]) using the program Coot ([@bib16]). Figures were generated with Pymol ([@bib11]).

2.10. *Xc*ACE activity during bacterial growth
----------------------------------------------

To examine *Xc*ACE localization, ACE activity in medium and in bacterial extracts was monitored along during bacterial growth using HHL as substrate as described above.

3. Results
==========

3.1. Presence of ACE orthologues in bacterial genomes
-----------------------------------------------------

Among 465 bacterial strains genomes screened, 26 sequences produced significant similarity (*E* value \< 0.5) with leech *Tt*ACE. Further analysis revealed that at least 22 sequences within 19 different bacterial strains within 8 generas potentially encode putative ACE-like enzymes. These species are ecologically as well as phylogenetically distant, since they are found amongst Cyanobacteria (*Gloeobacter violaceus*, gi: **[37522712]{.ul}**, gi: **[35213714]{.ul}**), Acidobacteria (*Solibacter usitatus*, gi: **[67858770]{.ul}**, gi: **[66769433]{.ul}**) and Proteobacteria of the subdivision alpha (*Erythrobacter litoralis*, gi: **[61100845]{.ul}**, gi: **[60736774]{.ul}**), delta (*Anaeromyxobacter dehalogenans*, gi:**[66855040]{.ul}**) and gamma (*X. citri*, gi: **[21241971]{.ul}**, gi: **[21107345]{.ul}**; *Xanthomonas oryzae*, gi: **[37931607]{.ul}**, gi: **[58583162]{.ul}**; *Xanthomonas campestris pv campestris*, gi:**[21230574]{.ul}**, gi: **[21112152]{.ul}**; *Shewanella oneidensis*, gi: **[24374038]{.ul}**, gi: **[24348510]{.ul}**) proteobacteria. All these predicted proteins share between 38 and 98% primary sequence identity between them, indicating a wide variety among the potential bacterial ACEs ([Fig. 1](#fig1){ref-type="fig"} and [Supplementary data](#app1){ref-type="sec"}). Nevertheless, all these sequences exhibit key ACE features such as the presence of two highly conserved consensus VCHASAWDFY and GANPGFHEA motifs surrounding a putative M2-catalytic site HexxH (data not shown).Fig. 1Homology of the bacterial ACE related to various ACEs in the phylogenetic tree. (A): Percentage of identity in amino acids between *Xc*ACE and various ACE-like enzymes primary sequences described or deduced from genomic sequences: Ndom, human N-domain ACE (gi: **[4732026]{.ul}**, residues 1--583); Cdom, human C-domain ACE (gi: **[4732026]{.ul}**, residues 641--1306); ACE2, human ACE2 (gi: **[71658783]{.ul}**); ACEr, *Drosophila melanogaster* ACEr (gi: **[73921650]{.ul}**); X camp, *Xanthomonas campestris* pv. *campestris* predicted dipeptidyl-carboxypeptidase (gi: **[66769433]{.ul}**); E lito, *Erythrobacter litoralis* predicted dipeptidyl-carboxypeptidase (gi: **[61100845]{.ul}**); G viol, *Gloeobacter violaceus* predicted dipeptidyl-carboxypeptidase (gi: **[37522712]{.ul}**). (B): unrooted cladogram indicating evolutionary relationships between the different ACE homologues among the living kingdom.

3.2. Molecular characterization of *Xc*ACE
------------------------------------------

We cloned an ACE homologue in the phytopathogenic bacterium *X. citri* corresponding to the sequence [XAC1217](XAC1217) (gi: **[21107356]{.ul}**, gene ID **[1155288]{.ul}**). The transcription of the *XcACE* gene was suggested by the sequence conservation upstream the start codon and is assessed by the presence of a specific 437-bp RT-PCR product in DNAse-treated, reverse-transcribed total RNA ([Fig. 2](#fig2){ref-type="fig"} ). The protein encoded by this gene, referred to as *Xc*ACE (*Xanthomonas citri* angiotensin-converting enzyme), is a 672 amino-acid protein. Hydrophobicity profile (SignalP V1.1 at [www.cbs.dtu.dk/services/SignalP](http://www.cbs.dtu.dk/services/SignalP)) indicates cleavage of a putative signal peptide between residues 26 and 27 of the native protein (...RDA↕AP...). There does not appear to be a motif encoding a transmembrane domain at the C-terminus or elsewhere in the mature molecule, suggesting that *Xc*ACE should exist only in a soluble form. Because of the mutation inserted, the recombinant proenzyme is slightly different from the native one in the N-terminal end (r*Xc*ACE: MQGPPVNPRLL *vs* n*Xc*ACE: MNPRLL). However, this difference does not change predictions about the signal peptide (hydrophobicity profile and cleavage site) (data not shown), indicating that the mature recombinant and native proteins have identical primary sequences. The mature enzyme has a theoretical molecular weight of 72 kDa and an isoelectric point of 5.72. Its primary structure includes all the residues implied in zinc (H^429^, H^433^ and E^457^), lisinopril (H^391^, A^392^, E^430^, K^556^, H^558^, Y^565^ and Y^568^) ([@bib32]) and captopril (Q^290^, K^556^, Y^565^, H^391^, H^558^ and Y^568^) ([@bib31]) binding. Thus the soluble, secreted enzyme should possess a single active site like the other ACEs found in invertebrates. Whereas two chloride atoms were observed bound to the human tACE, *Xc*ACE appears to be more similar to the N-domain in this respect, as it only has the chloride II binding site conserved (Y^230^ and R^567^), and only one amino acid among the three implicated in the binding of the first chloride atom (W^530^). The *Xc*ACE primary sequence has between 31 and 37% identity with the other known ACEs (human, *Drosophila* and leech) and 26% with *C. elegans* ACN-1 ([Fig. 1](#fig1){ref-type="fig"} and [Supplementary data](#app1){ref-type="sec"}).Fig. 2RT-PCR assay of the *Xc*ACE transcript. cDNA was generated and submitted to PCR (cycling parameters: 94 °C, 2 min; 94 °C, 45 s, 61 °C, 30 s, 72 °C, 1 min, for 25, 30 or 40 cycles, 72 °C, 4 min).Treatments of the different samples are indicated above the corresponding lane. The size of the expected band is indicated. L: DNA molecular weight marker, W: water control. The number of PCR cycles is indicated under each sample.

3.3. Biochemical characterization of *Xc*ACE
--------------------------------------------

### 3.3.1. Semi-purification

The semi-purification of *Xc*ACE procedure using FPLC ([Fig. 3](#fig3){ref-type="fig"}A) resulted in a fraction containing a protein band at the expected size for *Xc*ACE (∼ 75 kDa), as revealed by SDS-PAGE analysis of the different fractions obtained after each purification step (data not shown).Fig. 3Semi-purification and Western blot of *Xc*ACE. (A): FPLC profile of the last purification step (see [Section 2.8.1](#sec3){ref-type="sec"}), absorbance at 280 nm (full line), the gradient (dashed line) was from 0 to 50 mS/cm, arbitrary units of ACE activity (dotted line), the horizontal bar indicates the fractions pooled for further analysis. (B): Native and recombinant *Xc*ACE were analysed by SDS-PAGE followed by Western blot with the antiserum *HKCE*. Lane a, molecular-mass standards; lane b, human somatic ACE; lane c, native *XcACE*; lane d, recombinant *XcACE.* The band corresponding to XcACE is indicated (arrow).

### 3.3.2. Immunological characterization

Both native and recombinant *Xc*ACE were analysed by Western blotting and migrated with an apparent molecular weight of 72 kDa, matching theoretical predictions ([Fig. 3](#fig3){ref-type="fig"}B), and have a similar mobility on SDS-PAGE to deglycosylated human tACE ([@bib47]).

### 3.3.3. Enzymatic activity

*Xc*ACE shows dipeptidyl-carboxypeptidase activity, cleaving a carboxyterminal dipeptide from peptidic substrates. It generates AngII from AngI ([Fig. 4](#fig4){ref-type="fig"}A), hippuric acid from HHL ([Fig. 4](#fig4){ref-type="fig"}B), AcKP from AcSDAcKP ([Fig. 4](#fig4){ref-type="fig"}C), and Tyrosyl-glycyl-glycine (YGG) from Leu-enkephalin (data not shown). *Xc*ACE also displays an endopeptidase activity, as shown by its ability to hydrolyse the amidated substrate, Leu-enk-NH2 ([Fig. 4](#fig4){ref-type="fig"}D). As for AngI hydrolysis ([Fig. 4](#fig4){ref-type="fig"}E), the same results were obtained with recombinant *Xc*ACE (data not shown). *Xc*ACE activity depends on zinc binding. Indeed, hydrolysis of Mca-SDKP-DpaOH was abolished after zinc chelation with EDTA and dialysis but was restored by zinc addition (data not shown).Fig. 4Biochemical characterization of *Xc*ACE. Hydrolysis of various ACE substrates by native (n*Xc*ACE) (A--D) and recombinant (r*Xc*ACE) (E). Hydrolysis of angiotensin I (A), hydrolysis of HHL (B), AcSDAcKP (C), \[Leu5\]-enkephalin (D) and \[Leu5\]-enkephalinamide (E) by native *Xc*ACE. Hydrolysis of angiotensin I by recombinant XcACE (F). The specificity of the reactions was assessed in the presence of 10 μM captopril (dashed line). AngI, angiotensin I; AngII, angiotensin II; AH, hippuric acid; YGG, tyrosyl-glycyl-glycine. Chloride sensitivity of *Xc*ACE (F). Effect of chloride ions concentration on HHL hydrolysis by native (◇) *Xc*ACE, C-(ж) and N-domain (▲) of human somatic ACE.

### 3.3.4. Effect of chloride concentration

Native *Xc*ACE is already active in the absence of chloride ions. However, its activity in the presence of increasing chloride ion concentrations increases 3-fold. In this respect, *Xc*ACE Cl^−^ activation presents intermediate characteristics when compared to both N- and C-domain human ACE ([@bib34]). ([Fig. 4](#fig4){ref-type="fig"}F).

### 3.3.5. Effect of ACE inhibitors

Fosinoprilat is the most potent inhibitor of *Xc*ACE activity (IC~50~: 3.0 · 10^− 8^  ± 1.0 · 10^− 8^ M), whereas captopril is less efficient (1.6 · 10^− 7^  ± 0.1 · 10^− 7^ M). RXP 407 (1.9 · 10^− 6^  ± 1.5 · 10^− 6^ M) and Enalaprilat (3.8 · 10^− 6^  ± 2.8 · 10^− 6^ M) displayed IC~50~ values in the micromolar range. Perindoprilat (1.3 · 10^− 4^  ± 1.3 · 10^− 4^ M), delaprilat (3.7 · 10^− 5^  ± 1.7 · 10^− 5^ M) and lisinopril (4.7 · 10^− 5^  ± 4.3 · 10^− 5^ M), all containing carboxylate zinc-binding groups, were the least effective inhibitors of *Xc*ACE. Values are means ± standard error from three independent experiments.

3.4. Predicted structure of *Xc*ACE
-----------------------------------

As the crystal structures of human ACE ([@bib6], [@bib32]), ACE2 ([@bib40]) and the *Drosophila* AnCE ([@bib25]) all have the same fold, the 34% sequence identity of human tACE and bacterial *Xc*ACE allowed us to model with confidence the overall fold of *Xc*ACE based on the tACE structure (pdb code **[1O8A]{.ul}**). We identified active site residues that could account for the differences in inhibitor affinities (see [Section 4.2](#sec4){ref-type="sec"}) ([Fig. 5](#fig5){ref-type="fig"} ).Fig. 5Comparison of the charge of the active site between tACE and *Xc*ACE. ACE is represented as a surface with the positive charge indicated in blue and the negative in red. The zinc atom is represented (green), and some of the residues are indicated. Lisinopril (in yellow) is shown to orientate the active site. A, The active site viewed as a surface from the lysyl pocket for tACE (left) and XcACE (right). B, The active site cavity viewed from the outside for tACE (left) and XcACE (right). tACE is shown to have a higher negative charge in the lysyl binding pocket.

3.5. *Xc*ACE expression during bacterial growth and localization
----------------------------------------------------------------

Only background ACE activity was detected in the culture medium, which remains constant over time. In contrast, ACE activity in bacterial extract correlates bacterial growth indicating that *Xc*ACE is constituvely expressed and is likely to be secreted and further localised in the periplasmic space ([Fig. 6](#fig6){ref-type="fig"} ).Fig. 6*Xc*ACE activity during bacterial growth. Follow-up of bacterial growth by O.D. at 600 nm (◇) and ACE activity (nmoles hippuric acid generated) in culture medium (□) and within bacteria (○). Error bars were omitted for clarity.

4. Discussion
=============

4.1. ACE is an ancestral enzyme
-------------------------------

Databank analysis revealed the presence of putative ACE-encoding genomic DNA sequences in a very wide range of bacterial species, corresponding to a broad range of ecological lifestyles and terminal electron acceptor for growth ([@bib12]), suggesting that ACE is an ancestral enzyme. Characterization of *Xc*ACE constitutes the first evidence of the presence of an ACE-like enzyme in more distant organisms than cellular metazoans. Indeed, in contrast to *Xc*ACE, the amino-acid sequence of *L. donovani* dicarboxypeptidase (LdDCP) ([@bib18]) does not show any significant alignment with all other known ACEs, was not reported to hydrolyse Ang I to Ang II, and lacks conserved consensus motifs found in almost all ACE primary sequences (for references see the MEROPS database available at <http://merops.sanger.ac.uk/>). However, in contrast with *Leishmania*, none of the bacterial species putatively possessing an ACE mentioned in this study is known to be a human pathogen, whereas xanthomonadacaea are phytopathogens among which *X. citri* was chosen for technical reasons.

4.2. Structure--activity relationship of *Xc*ACE, a functional angiotensin-converting enzyme *in vivo* {#sec4}
------------------------------------------------------------------------------------------------------

The *Xc*ACE possesses a single M2 catalytic site and a signal peptide but no membrane anchor, like the ACE characterized in invertebrates. Despite the fact that the recombinant enzyme was expressed in a heterologous system, both native and recombinant forms display almost identical features, indicating a satisfactory purity of *Xc*ACE and strongly suggesting that the ACE in *X. citri* is a functional ACE enzyme *in vivo*. *Xc*ACE, like *Drosophila* AnCE (data not shown), is active in the absence of chloride ions and less sensitive to variations in chloride ion concentration than human C-domain ACE ([@bib20]). This characteristic is likely to be due to the absence in the primary sequence of *Xc*ACE, as in AnCE, of two key amino acids observed to bind ClI in human tACE (*Xc*ACE : R186H and R489K; AnCE : R1867Y and W485F, when compared to tACE). *Xc*ACE hydrolyses a broad range of substrates, including human N- and C-domain ACE specific substrates (AcSDAcKP and HHL, respectively). In addition to this dicarboxypeptidase activity, *Xc*ACE also acts as an endopeptidase, hydrolysing the C-terminal blocked amidated substrate \[Leu5\]-enkephalinamide. Western blot results using polyclonal antibody raised against the full-length human sACE protein show a unique band corresponding to *Xc*ACE, indicating that *Xc*ACE shares common epitopic features with the human enzyme. Molecular modelling allowed us to visualise the structural differences in the catalytic site. Key active site residues such as the zinc-binding motif, His^513^ and Tyr^526^ (tACE numbering) are conserved in *Xc*ACE and many other ACE-like enzymes. However, in line with the assay results, the non-conserved active site residues are neither identical to the C- or N-domain of human ACE, and are the presumed cause of the different substrate selectivity and inhibition profile of *Xc*ACE. Comparison of the *Xc*ACE model with either the human tACE or N-domain shows that lisinopril fits in the *Xc*ACE active site and retains most of the same binding interactions. The exception is in the lysyl pocket, which has features in common with AnCE or the human N-domain including a positively charged residue, lysine (equivalent to Arg^356^ in AnCE and Arg^350^ in the human N-domain) that appears to affect the overall charge of the pocket ([Fig. 5](#fig5){ref-type="fig"}). Indeed, similar to *Xc*ACE, neither AnCE nor the N-domain have as high affinity for lisinopril as tACE ([@bib30], [@bib45]). Furthermore, the difference in affinity of *Xc*ACE and tACE for inhibitors with hydrophobic P1 groups (*i.e.* lisinopril, delaprilat and perindoprilat) could be attributed to the difference in hydrophobicity of the S1 subsite. *Xc*ACE has a threonine and tyrosine in contrast to Phe^512^ and Val^518^ in tACE ([Fig. 5](#fig5){ref-type="fig"}). The N-terminal aspartate, *N*-acetyl groups and the C-terminal amide of RXP407 are the reported determinants required for its remarkable N-domain specificity ([@bib13]). Of the four possible residues suggested for N-domain selective recognition of RXP 407 ([@bib6], [@bib41]), *Xc*ACE only retains the threonine (T^496^ in the N-domain) and has a lysine which replaces Arg^500^ of the N-domain. This, combined with the hydrophobic P1 group, may be the reason that RXP407 is not a strong inhibitor for *Xc*ACE. The affinity of *Xc*ACE for fosinoprilat is harder to rationalise as it has been modelled in different conformations for the N- and C-domains of human ACE ([@bib41]). However, *Xc*ACE retains all the residues suggested to be involved in inhibitor binding with both domains of human ACE.

4.3. Putative physiological roles
---------------------------------

The biological functions of *Xc*ACE remain unclear but could constitute the original, ancestral function of ACE. *Xc*ACE is soluble and its sequence exhibits a signal peptide indicating, along with the absence of ACE activity in the culture medium, that *Xc*ACE is a secreted enzyme which is trapped into the periplasmic space. The constitutive expression could indicate an important function for ACE in *X. citri*, as a possible role for the enzyme in peptidoglycan remodelling, a critical parameter in environmental adaptation. This is in line with the characterization in the periplasm of other gram negative bacteria of VanX [d]{.smallcaps}-alanyl-[d]{.smallcaps}-alanine dipeptidase, a regulated carboxypeptidase that is responsible for Vancomycin resistance ([@bib28]). *Xc*ACE could also participate in *X.citri* pathogenicity within the cocktail of degradative enzymes required during plant infection. Interestingly, in this regard, ACE inhibitors are found in hydrolysates of plants sensitive to the "black rot" caused by *Xanthomonas*, including rice and soybean ([@bib19], [@bib46]). The large number of substrates of *Xc*ACE does not exclude a possible function of protein degradation that might generate dipeptides for protein biosynthesis. To this extent, it is interesting to note that ACE is highly expressed in the digestive tract of all metazoan species presenting an active ACE.

4.4. Evolutionary and phylogenetic aspects
------------------------------------------

One of the most relevant questions raised by this study deals with phylogenetic considerations and evolution of ACE. Its presence in eukarya as well as in bacteria indicates that the enzyme could have appeared before the divergence between these two groups. This strongly suggests that *Xc*ACE is the most ancestral present-day representative of ACE characterized to date. However, as all completely sequenced genomes of plants, algaes and mycetes lack ACE, caution should be exercised with this hypothesis. The presence of an ACE-like enzyme in bacteria could also be the result of a horizontal gene transfer from eucaryotic to bacterial species. However, conservation in sequences surrounding the *ACE* gene, suggestive of mobile genetic elements, is not observed within 30 kb of the gene in seven distinct bacterial strains (data not shown). Furthermore, the parasitic bacterial species with an ACE-like gene are all hosted by organisms lacking the enzyme. In addition, not all bacterial species with a putative ACE gene are parasitic. Thus, the presence of ACE in bacteria, like the situation encountered in annelids, is unlikely to be related to parasitism, suggesting that bacterial ACE, represented herein by *Xc*ACE, corresponds to the ancestral, original enzyme.

4.5. Ancestral ACE is neither related to the N- nor the C-domain of mammalian ACE
---------------------------------------------------------------------------------

*Xc*ACE exhibits a similar primary sequence identity with both N- and C-domains and, although *Xc*ACE cleaves the N-domain substrate AcSDAcKP, the N-domain specific inhibitor RXP407 is not a potent inhibitor of *Xc*ACE activity. In contrast, lisinopril, a C-domain-related inhibitor, is less efficient than captopril, related to the N-domain, though most of the residues for binding of both are conserved. Thus, from the biochemical and the structural properties of *Xc*ACE it is not possible to ascribe this bacterial enzyme to either the mammalian N-or C-domain of human ACE. The primitive ACE would then not be closer to either domain of the mammalian enzyme, in contrast to what was previously suggested ([@bib4], [@bib22], [@bib27]).

5. Conclusion
=============

This work describes the cloning, expression, purification, biochemical characterization, molecular modelling and localization of *Xc*ACE, the first ACE-like enzyme in a bacterium, *X. citri*. Taken together, our results bring the evidence of the presence of a functional ACE in prokaryotes, in contrast to the previous hypothesis about the latter appearance of ACE during phylogeny. It also appears that sequence/structure conservation of ACE enabled preservation of dipeptidase activity during evolutionary specialisation. *Xc*ACE is the most ancestral ACE present-day representative and has features in common to both the N- and the C-domain of mammalian somatic ACE. It is possible that this ancestral ACE was a poorly specialised protease which has acquired its present specialisation over a long evolutionary period. However, the biological function(s) as well as the endogenous substrates and/or inhibitors of bacterial ACE remain to be characterized. To clarify these issues, the use of ACE inhibitors *in vivo* and the generation of a mutant bacterial strain lacking ACE may be helpful. Some of these functions of ACE might also be conserved in humans, and their characterization could lead to a better understanding of the evolution of this crucial enzyme.
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